Literature DB >> 19053233

Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor.

Ntsang M Nebane1, Dow P Hurst, Carl A Carrasquer, Zhuanhong Qiao, Patricia H Reggio, Zhao-Hui Song.   

Abstract

We have used the substituted-cysteine accessibility method (SCAM) to map the residues in the sixth membrane-spanning segment of the CB2 cannabinoid receptor that contribute to the surface of the water-accessible binding-site crevice. Using a background of the mutant C2.59S which is relatively insensitive to the methanethiosulfonate (MTS) reagents, we mutated to cysteine, one at a time, 34 consecutive residues in TMH6 of the CB2 receptor. These mutant receptors were then expressed in HEK293 cells. By incubating HEK293 cells stably transfected with CB2 receptors with the small, charged, hydrophilic, thiol-specific reagent methanethiosulfonate ethylammonium (MTSEA), [(3)H]CP55940 binding was significantly inhibited for six mutant receptors. All six of the mutants that reacted with MTSEA were protected from the reaction when pretreated with the cannabinoid agonist WIN55212-2, suggesting that MTSEA modification occurred within the binding crevice. Therefore, the side chains of the residues at these reactive loci (V6.51, L6.52, L6.54, M6.55, L6.59, and T6.62) are on the water-accessible surface of the binding-site crevice. These residues are extracellular to the TMH6 CWXP hinge motif. The pattern of accessibility is consistent with a alpha-helical conformation for this segment of TMH6. Molecular modeling studies performed in the context of the CB2 model show that V6.51, L6.52, L6.54, M6.55, L6.59, and T6.62 face into the CB2 binding pocket, further confirming our SCAM results. These results are similar to the accessibility patterns determined by SCAM studies of TMH6 in the opioid and dopamine D2 receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053233      PMCID: PMC4791095          DOI: 10.1021/bi8007802

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  46 in total

1.  Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment.

Authors:  J A Javitch; J A Ballesteros; J Chen; V Chiappa; M M Simpson
Journal:  Biochemistry       Date:  1999-06-22       Impact factor: 3.162

2.  Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment.

Authors:  J A Javitch; D Fu; G Liapakis; J Chen
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

3.  Substituted-cysteine accessibility method.

Authors:  A Karlin; M H Akabas
Journal:  Methods Enzymol       Date:  1998       Impact factor: 1.600

4.  Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells.

Authors:  M E Abood; K E Ditto; M A Noel; V M Showalter; Q Tao
Journal:  Biochem Pharmacol       Date:  1997-01-24       Impact factor: 5.858

5.  Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat.

Authors:  N E Buckley; S Hansson; G Harta; E Mezey
Journal:  Neuroscience       Date:  1998-02       Impact factor: 3.590

Review 6.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

7.  Calculating receptor number from binding experiments using same compound as radioligand and competitor.

Authors:  A DeBlasi; K O'Reilly; H J Motulsky
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

8.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

Authors:  D Shire; B Calandra; M Rinaldi-Carmona; D Oustric; B Pessègue; O Bonnin-Cabanne; G Le Fur; D Caput; P Ferrara
Journal:  Biochim Biophys Acta       Date:  1996-06-07

9.  Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.

Authors:  P Gouldson; B Calandra; P Legoux; A Kernéis; M Rinaldi-Carmona; F Barth; G Le Fur; P Ferrara; D Shire
Journal:  Eur J Pharmacol       Date:  2000-07-28       Impact factor: 4.432

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  18 in total

1.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

2.  Global fold of human cannabinoid type 2 receptor probed by solid-state 13C-, 15N-MAS NMR and molecular dynamics simulations.

Authors:  Tomohiro Kimura; Krishna Vukoti; Diane L Lynch; Dow P Hurst; Alan Grossfield; Michael C Pitman; Patricia H Reggio; Alexei A Yeliseev; Klaus Gawrisch
Journal:  Proteins       Date:  2013-10-17

3.  Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.

Authors:  Evangelia Kotsikorou; Karla E Madrigal; Dow P Hurst; Haleli Sharir; Diane L Lynch; Susanne Heynen-Genel; Loribelle B Milan; Thomas D Y Chung; Herbert H Seltzman; Yushi Bai; Marc G Caron; Larry Barak; Mary E Abood; Patricia H Reggio
Journal:  Biochemistry       Date:  2011-06-01       Impact factor: 3.162

Review 4.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

5.  Methods for the Development of In Silico GPCR Models.

Authors:  Paula Morales; Dow P Hurst; Patricia H Reggio
Journal:  Methods Enzymol       Date:  2017-07-14       Impact factor: 1.600

6.  Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.

Authors:  Mohammed Alqarni; Kyaw Zeyar Myint; Qin Tong; Peng Yang; Patrick Bartlow; Lirong Wang; Rentian Feng; Xiang-Qun Xie
Journal:  Biochem Biophys Res Commun       Date:  2014-08-19       Impact factor: 3.575

7.  Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Authors:  María Gómez-Cañas; Gemma Navarro; Paula Morales; Dow P Hurst; Francisco J Carrillo-Salinas; Laura Lagartera; Ruth Pazos; Pilar Goya; Patricia H Reggio; Carmen Guaza; Rafael Franco; Javier Fernández-Ruiz; Nadine Jagerovic
Journal:  J Med Chem       Date:  2016-07-06       Impact factor: 7.446

8.  Distinct second extracellular loop structures of the brain cannabinoid CB(1) receptor: implication in ligand binding and receptor function.

Authors:  Joong-Youn Shim; James Rudd; Tomas T Ding
Journal:  Proteins       Date:  2011-02

9.  Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.

Authors:  Jianping Hu; Zhiwei Feng; Shifan Ma; Yu Zhang; Qin Tong; Mohammed Hamed Alqarni; Xiaojun Gou; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2016-05-26       Impact factor: 4.956

10.  Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments.

Authors:  Elvis K Tiburu; Sergiy Tyukhtenko; Lalit Deshmukh; Olga Vinogradova; David R Janero; Alexandros Makriyannis
Journal:  Biochem Biophys Res Commun       Date:  2009-05-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.